Of 6 participants enrolled (mean age 33.3 years; body mass index 28.83kg/m²), 5 completed the study. One participant withdrew (day 7; family emergency) after receiving atogepant. Median times to maximum plasma concentration were 1.0 and 1.5 hours postdose, mean terminal elimination half-life was 18.46 and 11.64 hours for atogepant and total radioactivity, respectively. Mean atogepant/total radioactivity ratio for systemic exposure (area under concentration-time curve) was ≈0.75, indicating unchanged parent drug was the major circulating species in plasma. Approximately 81% of radioactivity was recovered in feces, 8% in urine. Mean total radioactivity recovery in feces and urine was ≈89% over 336 hours after dosing. In feces, 42% of the dose was recovered as parent drug due to unabsorbed drug, biliary excretion, intestinal secretion, or combination. Atogepant and metabolite M23 were the only radiometric peaks in plasma; at least 11 metabolites were detected in feces (each <10% of radioactive dose). Metabolite M23 represented ≈15% of radioactive exposure in plasma, was not long-lasting, and tentatively characterized as dioxygenated methylated glucuronide of atogepant. No treatment-emergent adverse events or serious adverse events occurred. No clinically meaningful changes in laboratory, vital, or electrocardiogram parameters were observed.